Top

Published in:

16-12-2023 | Duchenne Muscular Dystrophy | AdisInsight Report

Vamorolone: First Approval

Author: Susan J. Keam

Published in: Drugs | Issue 1/2024

Abstract

Vamorolone (AGAMREE^®) is an oral, selective, dissociative corticosteroid developed by ReveraGen BioPharma and Santhera Pharmaceuticals for the treatment of patients with muscular dystrophy. Vamorolone was approved in October 2023 for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older in the USA and received a positive opinion in the EU in October 2023 for the treatment of DMD in patients 4 years of age and older. This article summarizes the milestones in the development of vamorolone leading to this first approval for DMD.

Available only for authorised users

Orphanet. Duchenne and Becker muscular dystrophy. 2020. https://www.orpha.net/. Accessed 14 Nov 2023.

Kourakis S, Timpani CA, Campelj DG, et al. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis. 2021;16(1):117.CrossRefPubMedPubMedCentral

Ferizovic N, Summers J, de Zárate IBO, et al. Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE. 2022;17(3): e0265879.CrossRefPubMedPubMedCentral

Dang UJ, Ziemba M, Clemens PR, et al. Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. Hum Mol Genet. 2020;29(15):2481–95.CrossRefPubMedPubMedCentral

Fiorillo AA, Tully CB, Damsker JM, et al. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. Physiol Genomics. 2018;50(9):735–45.CrossRefPubMedPubMedCentral

ReveraGen BioPharma Inc., Santhera Pharmaceuticals. Santhera and ReveraGen announce FDA acceptance of new drug application for vamorolone in Duchenne muscular dystrophy [media release]. 9 Jan 2023. https://www.reveragen.com.

Heier CR, Yu Q, Fiorillo AA, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019;2(1): e201800186.CrossRefPubMedPubMedCentral

Liu X, Wang Y, Gutierrez JS, et al. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 2020;117(39):24285–93.CrossRefPubMedPubMedCentral

Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol. 2022;79(10):1005–14.CrossRefPubMedPubMedCentral

10.

Catalyst Pharmaceuticals Inc. Vamorolone: US prescribing information. 2023. https://agamree.com/. Accessed 17 Nov 2023.

11.

Santhera Pharmaceuticals. Santhera receives U.S. FDA approval of AGAMREE^® (vamorolone) for the treatment of Duchenne muscular dystrophy [media release]. Oct 27 2023. https://www.santhera.com/.

12.

European Medicines Agency. Agamree (vamorolone): CHMP summary of positive opinion. 2023. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/agamree. Accessed 17 Nov 2023.

13.

Santhera Pharmaceuticals Inc. Santhera submits marketing authorization application to the UK MHRA for vamorolone in Duchenne muscular dystrophy [media release]. 2 Mar 2023. https://www.santhera.com.

14.

Santhera Pharmaceuticals, ReveraGen BioPharma Inc. Santhera and ReveraGen announce first participant dosed in FDA-funded phase 2 pilot study with vamorolone in Becker muscular dystrophy [media release]. 22 Aug 2022. https://www.santhera.com.

15.

Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals acquires exclusive North American license for vamorolone for Duchenne muscular dystrophy from Santhera Pharmaceuticals [media release]. 19 Jul 2023. https://www.catalystpharma.com.

16.

Santhera Pharmaceuticals Inc. Santhera grants exclusive North America license for vamorolone to Catalyst Pharmaceuticals in deal valued at up to USD 231 million plus royalties [media release]. 20 Jan 2023. https://www.santhera.com.

17.

Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals to license North American rights to vamorolone for Duchenne muscular dystrophy from Santhera Pharmaceuticals [media release]. 19 Jul 2023. https://www.catalystpharma.com.

18.

Sperogenix Therapeutics. Sperogenix and Santhera entered into exclusive license agreement for vamorolone in rare diseases in the Greater China region [media release]. 4 Jan 2022. https://www.sperogenix.com/.

19.

Santhera Pharmaceuticals. Santhera enters into exclusive license agreement with Sperogenix for vamorolone in rare diseases in the Greater China region [media release]. 4 Jan 2022. https://www.santhera.com.

20.

Actelion Ltd., ReveraGen BioPharma Inc. Actelion obtains an option to in-license vamorolone from ReveraGen [media release]. 3 Nov 2016. https://www.reveragen.com/.

21.

Idorsia Ltd. Idorsia assigns and transfers agreement with ReveraGen to Santhera [media release]. 2 Sep 2020. https://www.idorsia.com/.

22.

Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013;5(10):1569–85.CrossRefPubMedPubMedCentral

23.

Conklin LS, Damsker JM, Hoffman EP, et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018;136:140–50.CrossRefPubMedPubMedCentral

24.

Hoffman EP, Riddle V, Siegler MA, et al. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids. 2018;134:43–52.CrossRefPubMedPubMedCentral

25.

McCormack NM, Nguyen NY, Tully CB, et al. Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice. iScience. 2023;26(7): 107161.CrossRefPubMedPubMedCentral

26.

Sreetama SC, Chandra G, Van der Meulen JH, et al. Membrane stabilization by modified steroid offers a potential therapy for muscular dystrophy due to dysferlin deficit. Mol Ther. 2018;26(9):2231–42.CrossRefPubMedPubMedCentral

27.

Mavroudis PD, van den Anker J, Conklin LS, et al. Population pharmacokinetics of vamorolone (VBP15) in healthy men and boys with Duchenne muscular dystrophy. J Clin Pharmacol. 2019;59(7):979–88.CrossRefPubMedPubMedCentral

28.

Leinonen M, Hasham S, Guglieri M, et al. Efficacy and safety of vamorolone during 48-week treatment in patients with Duchenne muscular dystrophy (DMD) in the VBP15-004 study [abstract no. and poster]. In: MDA clinical & scientific conference USA. 2022.

29.

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019;93(13):e1312–23.CrossRefPubMedPubMedCentral

30.

Smith EC, Conklin LS, Hoffman EP, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17(9): e1003222.CrossRefPubMedPubMedCentral

31.

Mah JK, Clemens PR, Guglieri M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open. 2022;5(1): e2144178.CrossRefPubMedPubMedCentral

Title: Vamorolone: First Approval
Author: Susan J. Keam
Publication date: 16-12-2023
Publisher: Springer International Publishing
Keywords: Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Prednisolone
Muscular Dystrophy
Muscular Dystrophy
Published in: Drugs / Issue 1/2024
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-023-01986-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vamorolone: First Approval

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

New Therapies on the Horizon for Primary Biliary Cholangitis

Spesolimab for the Treatment of Generalized Pustular Psoriasis

Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”

Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension

Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage

Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”